VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Cancer EPCAM protein vaccine
Vaccine Information
  • Vaccine Name: Cancer EPCAM protein vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0011370
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: EPCAM (GA733)
  • EPCAM gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Vaccination Protocol: Mice were immunized with 100 lg of Ab2 BR3E4 in CFA/IFA on days 0, 12, and 33, or with 5 lg alum-precipitated GA733-2E on days 0, 14, and 28 (Maruyama et al., 2000).
  • Challenge Protocol: Immunized mice (4±6/group) were challenged s.c. with 4 x 107 CT26-ALGA710-3H cells expressing the GA733 antigen or with parental, antigen-negative
    CT26 cells 2 weeks after the last immunization. Tumors were measured with a caliper twice each week for up to 2 months after the challenge (Maruyama et al., 2000).
  • Efficacy: The full-length GA733 (epcam) antigen expressed by recombinant adenovirus inhibited the growth of established tumors in mice (Maruyama et al., 2000).
References
Maruyama et al., 2000: Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer immunology, immunotherapy : CII. 2000; 49(3); 123-132. [PubMed: 10881691].